Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Enzon Pharmaceuticals Inc
ENZN | US
0.05
USD-0.01
-16.67%
ENZN | US
About Enzon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.05
Open
0.03
High
0.05
Low
0.02
Enzon Pharmaceuticals Inc. together with its subsidiaries engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford New Jersey.
View LessENZN | US
Risk
133.7
Sharpe
-0.34
Luna's Score
28/100
Recommendation
Sell
Luna says (ENZN | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
144.2%1 month
133.7%3 months
141.5%6 months
137.9%Returns
Fundamental Ratios
PE
12.00
Fwd. PE
-
Price to book
2.86
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
38.29
Ent. to rev.
608.03
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
3.57M
MarketCap(USD)
3.57M
Div. yield
-
Op. margin
-1.25K
Erngs. growth
29.10
Rev. growth
-10.30
Ret. on equity
3.42
Short ratio
1.71
Short perc.
0.68
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.05
Range1M
0.05
Range3M
0.06
Volumes: Market Activity
Rel. volume
6.47
Price X volume
18.68K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 38.29 | 0.53 | Expensive |
| Ent. to Revenue | 608.03 | 3,967.00 | Cheaper |
| PE Ratio | 12.00 | 41.03 | Cheaper |
| Price to Book | 2.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 141.46 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 3.57M | 3.66B | Emerging |
